Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...
AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive ...
The mice were treated with anti-CTLA-4 and either daily or biweekly DNase I. Response was monitored by measuring tumor volume. Key Highlights: Data demonstrates beneficial effects of targeting NETs ...
The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...
OncoImmune develops novel immune-modulators targeting innate checkpoint mechanisms involving CD24–Siglec10 signaling as well as potential best-in-class anti-CTLA-4 antibody therapy that can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback